3PBIOVIAN

Dámaso Molero Sánchez - CEO, 3PBIOVIAN The 2024 combination of 3P Biopharmaceuticals and Biovian gives 3PBIOVIAN greater scale and a broader technology base as Dámaso Molero Sánchez looks towards the CDMO's next phase of growth. He sets out the rationale

The appointment of Ponchi marking an important milestone in the company's global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.

Pamplona, September 15, 2026. 3PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company's global commercial strategy and further strengthening its commercial leadership as the company co

The collaborative initiative has successfully identified tumor-specific T cell receptors using single-cell sequencing and artificial intelligence, paving the way for future personalized cancer treatments. 3PBIOVIAN is part of the PITÁGORAS consortium, a s

By 3PBIOVIAN's USP Development and Technical Service teams Decisions made early in recombinant protein development have lasting impacts on product quality, manufacturability, timelines, and cost. In fact, many common chemistry, manufacturing, and controls